222 related articles for article (PubMed ID: 18704622)
1. Molecular and clinical investigations in patients with low-renin hypertension.
Mackenzie IS; Brown MJ
Clin Exp Nephrol; 2009 Feb; 13(1):1-8. PubMed ID: 18704622
[TBL] [Abstract][Full Text] [Related]
2. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Activated intrarenal renin-angiotensin system is correlated with high blood pressure in humans.
Kobori H; Fu Q; Crowley SD; Gonzalez-Villalobos RA; Campos RR
J Appl Physiol (1985); 2010 Dec; 109(6):2003. PubMed ID: 21148352
[No Abstract] [Full Text] [Related]
3. Counterpoint: Activation of the intrarenal renin-angiotensin system is the dominant contributor to systemic hypertension.
Navar LG
J Appl Physiol (1985); 2010 Dec; 109(6):1998-2000; discussion 2015. PubMed ID: 21148349
[No Abstract] [Full Text] [Related]
4. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Sympathetic nervous system, plasma volume, and hypertension.
Christensen NJ
J Appl Physiol (1985); 2010 Dec; 109(6):2003. PubMed ID: 21188813
[No Abstract] [Full Text] [Related]
5. A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model.
Hallow KM; Lo A; Beh J; Rodrigo M; Ermakov S; Friedman S; de Leon H; Sarkar A; Xiong Y; Sarangapani R; Schmidt H; Webb R; Kondic AG
Am J Physiol Regul Integr Comp Physiol; 2014 May; 306(9):R647-62. PubMed ID: 24500431
[TBL] [Abstract][Full Text] [Related]
6. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system.
Cohn JN
J Appl Physiol (1985); 2010 Dec; 109(6):2006-7. PubMed ID: 21188834
[No Abstract] [Full Text] [Related]
7. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Activation of the sympathetic nervous system is the dominant contributor to systemic hypertension.
Negrao CE; Negrao MV
J Appl Physiol (1985); 2010 Dec; 109(6):2006. PubMed ID: 21188817
[No Abstract] [Full Text] [Related]
8. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system.
Rohrwasser A
J Appl Physiol (1985); 2010 Dec; 109(6):2007. PubMed ID: 21188818
[No Abstract] [Full Text] [Related]
9. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Dominant contributors for systemic hypertension--who leads, who follows?
Braga VA
J Appl Physiol (1985); 2010 Dec; 109(6):2007-8. PubMed ID: 21188840
[No Abstract] [Full Text] [Related]
10. Rebuttal from Navar.
Navar LG
J Appl Physiol (1985); 2010 Dec; 109(6):2001-2. PubMed ID: 21148351
[No Abstract] [Full Text] [Related]
11. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Systemic hypertension--a "ratologist" point of view.
Julien C
J Appl Physiol (1985); 2010 Dec; 109(6):2004. PubMed ID: 21188799
[No Abstract] [Full Text] [Related]
12. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Intrarenal angiotensin II generation as a hypertensinogenic mechanism.
Gonzalez-Villalobos RA; Fuchs S
J Appl Physiol (1985); 2010 Dec; 109(6):2013. PubMed ID: 21188829
[No Abstract] [Full Text] [Related]
13. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. AT1 receptors in the kidney mediate the chronic hypertensive response to angiotensin II.
Crowley SD
J Appl Physiol (1985); 2010 Dec; 109(6):2012-3. PubMed ID: 21188828
[No Abstract] [Full Text] [Related]
14. Point: Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension.
Esler M; Lambert E; Schlaich M
J Appl Physiol (1985); 2010 Dec; 109(6):1996-8; discussion 2016. PubMed ID: 20185633
[No Abstract] [Full Text] [Related]
15. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Chronic activation of sympathetic nervous system and systemic hypertension--stress shows the way.
Fontes MA; Xavier CH
J Appl Physiol (1985); 2010 Dec; 109(6):2004-5. PubMed ID: 21188815
[No Abstract] [Full Text] [Related]
16. Interpreting stimulated plasma renin and aldosterone to select physiologically individualized therapy for resistant hypertension: importance of the class of stimulating drugs.
Huang X; Li J; Liu L; Chen G; Yi Y; Li P; Wu Y; Xu Y; Bao H; Yu L; Qin X; Zhang Y; Wang B; Li J; Fan Hou F; Huo Y; Cheng X; Spence JD
Hypertens Res; 2019 Dec; 42(12):1971-1978. PubMed ID: 31562418
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Resistant and Refractory Hypertension.
Acelajado MC; Hughes ZH; Oparil S; Calhoun DA
Circ Res; 2019 Mar; 124(7):1061-1070. PubMed ID: 30920924
[TBL] [Abstract][Full Text] [Related]
18. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Systemic hypertension--involvement of the CNS to this complex puzzle.
Moreira TS; Takakura AC; Antunes VR
J Appl Physiol (1985); 2010 Dec; 109(6):2004. PubMed ID: 21188814
[No Abstract] [Full Text] [Related]
19. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
[TBL] [Abstract][Full Text] [Related]
20. Unsuccessfully Treated Hypertension: A Major Public Health Problem With a Potential Solution.
Furberg CD; Sealey JE; Blumenfeld JD
Am J Hypertens; 2017 Sep; 30(9):857-860. PubMed ID: 28482060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
